EWTX
Edgewise Therapeutics, Inc.
There isn't enough reported data to score EWTX yet.
EWTX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Unavailable |
EWTX's profitability is currently healthy. There isn't enough data to rate its revenue, cash flow and balance sheet.
EWTX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 5.5x | $45.17 | -1.4% |
| Fair | 5.5x | $45.41 | -0.9% |
| Expensive | 5.6x | $45.66 | -0.4% |
| Current | 5.6x | $45.82 | — |
Historical ranges are pointers, not guarantees.
EWTX's PE is 5.6x, but its earnings don't support one, so it isn't a reliable read right now.
EWTX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect EWTX's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
EWTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $8.19 | +$9.77 |
| Q2 2026 | -$1.85 | -$0.30 |
| Q1 2026 | -$1.66 | -$0.11 |
| Q4 2025 | -$1.63 | -$0.18 |
| Q3 2025 | -$1.58 | -$0.09 |
| Q2 2025 | -$1.55 | -$0.01 |
| Q1 2025 | -$1.55 | -$0.01 |
| Q4 2024 | -$1.45 | +$0.12 |
EWTX has returned to profit: it earned $8.19 per share over the past year, after losing money the year before.
EWTX Quarterly Revenue
EWTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$42.5M | -$9.9M |
| Q1 2026 | -$42.8M | -$4.9M |
| Q2 2025 | -$32.6M | -$6.3M |
| Q1 2025 | -$37.9M | -$9M |
| Q3 2024 | -$27.4M | -$4.9M |
| Q2 2024 | -$26.3M | -$5.3M |
| Q1 2024 | -$28.9M | -$1.7M |
| Q4 2023 | -$27M | -$11.9M |
EWTX has burned cash in almost every quarter: −$202M over the past year, against −$124M the year before.
EWTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +12% | +13.2M shares |
| 1 year | +15% | +15.4M shares |
| 3 years | +91% | +57.5M shares |
| 5 years | +494% | +101M shares |
EWTX has 121M diluted shares, up 15% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
EWTX Net Leverage
EWTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.1 | Neutral |
| Stochastic | 58.6 | Neutral |
EWTX's weekly RSI is 61 (neutral) and its Stochastic is 59 (neutral).
EWTX PE vs Healthcare Sector
EWTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $40.8 | 12% above |
| 20 week MA | $41.9 | 9.4% above |
| 50 week MA | $35.1 | 31% above |
| 100 week MA | $26.9 | 70% above |
| 200 week MA | $20.7 | 122% above |
EWTX is in an uptrend: it's above all five of its weekly moving averages, and 122% above its 200-week average.
EWTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $30.0 | $16.0 | -47% |
| 2022 | $16.0 | $8.55 | -47% |
| 2023 | $8.55 | $10.9 | +28% |
| 2024 | $10.9 | $28.7 | +163% |
| 2025 | $28.7 | $26.4 | -8.3% |
| 2026 YTD | $26.4 | $45.8 | +74% |
EWTX's yearly returns have swung widely, from +163% in 2024 to −47% in 2022. It's up 74% so far in 2026.